Authors: Cocquyt, V Van Belie, S Reinhardt, RR Decramer, MLA O'Brien, M Schellens, JHM Borms, M Verbeke, L Van Aelst, F De Smet, M Carides, AD Eldridge, K Gertz, BJ

Citation: V. Cocquyt et al., Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis, EUR J CANC, 37(7), 2001, pp. 835-842

Authors: Campos, D Pereira, JR Reinhardt, RR Carracedo, C Poli, S Vogel, C Martinez-Cedillo, J Erazo, A Wittreich, J Eriksson, LO Carides, AD Gertz, BJ

Citation: D. Campos et al., Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone, J CL ONCOL, 19(6), 2001, pp. 1759-1767

Authors: Cheng, CM Reinhardt, RR Lee, WH Joncas, G Patel, SC Bondy, CA

Citation: Cm. Cheng et al., Insulin-like growth factor 1 regulates developing brain glucose metabolism, P NAS US, 97(18), 2000, pp. 10236-10241

Authors: Navari, RM Reinhardt, RR Gralla, RJ Kris, MG Hesketh, PJ Khojasteh, A Kindler, H Grote, TH Pendergrass, K Grunberg, SM Carides, AD Gertz, BJ

Citation: Rm. Navari et al., Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptorantagonist, N ENG J MED, 340(3), 1999, pp. 190-195